Literature DB >> 2717294

High incidence of upper gastrointestinal tract involvement in children with Crohn disease.

C Lenaerts1, C C Roy, M Vaillancourt, A M Weber, C L Morin, E Seidman.   

Abstract

This retrospective study of Crohn disease in 230 children and adolescents with a mean age of 12.5 years at the time of diagnosis and an average follow-up of 6.6 years showed that 30% had lesions of the esophagus, stomach, and duodenum. Three patients had Crohn disease isolated to the upper gastrointestinal tract. The 169 patients with both small and large bowel disease were at greater risk (33%, P less than .05) of having upper gastrointestinal lesions than the 37 with isolated small bowel disease and the 21 with disease limited to the colon and/or rectum. An aggregate of symptoms and signs more likely present in those with upper gastrointestinal involvement included: dysphagia, pain when eating, nausea and/or vomiting, and aphthous lesions of the mouth. Furthermore, weight loss was more severe and hypoalbuminemia more frequent. Because upper gastrointestinal series x-ray studies failed to detect upper gastrointestinal lesions in 13 patients of 69 of those with upper gastrointestinal disease, endoscopy should be considered in all children and adolescents in whom a diagnosis of Crohn disease is entertained. Endoscopy and biopsy of the upper gastrointestinal tract should be done in any patient with symptoms suggestive of proximal involvement. Finally, in view of the fact that endoscopy established the diagnosis of Crohn disease in five patients previously thought to have chronic ulcerative colitis, the procedure should routinely be performed in all patients with chronic ulcerative colitis or indeterminate colitis before surgery is performed.

Entities:  

Mesh:

Year:  1989        PMID: 2717294

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  27 in total

Review 1.  Pediatric gastritis and peptic ulcer disease.

Authors:  U Blecker; D I Mehta; B D Gold
Journal:  Indian J Pediatr       Date:  1999 Sep-Oct       Impact factor: 1.967

2.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 3.  Chronic inflammatory bowel disease.

Authors:  I W Booth
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

Review 4.  The endoscopic findings of the upper gastrointestinal tract in patients with Crohn's disease.

Authors:  Yoshiki Nomura; Kentaro Moriichi; Mikihiro Fujiya; Toshikatsu Okumura
Journal:  Clin J Gastroenterol       Date:  2017-07-10

5.  Crohn's disease confined to the duodenum: A case report.

Authors:  Dong Jin Song; Il Soon Whang; Hyung Wook Choi; Cheol Yun Jeong; Sung Hoon Jung
Journal:  World J Clin Cases       Date:  2016-06-16       Impact factor: 1.337

6.  Esophageal Crohn's disease: treat the inflammation, not just the symptoms.

Authors:  P L Beck; T E Lay; P K Blustein
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

Review 7.  Crohn's Disease of the Esophagus, Duodenum, and Stomach.

Authors:  David M Schwartzberg; Stephen Brandstetter; Alexis L Grucela
Journal:  Clin Colon Rectal Surg       Date:  2019-06-17

8.  Ulcerative colitis complicated by gastroduodenal lesions.

Authors:  M Sasaki; K Okada; S Koyama; U Yoshioka; H Inoue; Y Fujiyama; T Bamba
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

9.  The antegrade colonogram: extending the small bowel follow through for children suspected of having colonic disease.

Authors:  B C Dangman; A M Leichtner; R L Teele
Journal:  Pediatr Radiol       Date:  1992

10.  ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Authors:  Gary R Lichtenstein; Edward V Loftus; Kim L Isaacs; Miguel D Regueiro; Lauren B Gerson; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2018-03-27       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.